This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Clinical Development Remove Genotype Remove Hormones Related Topics
In-Vitro In-Vivo Bacteria Licensing Gene Therapy Trials Life Science Genetics Antibody Gene More Related Topics >
article thumbnail

Risk adjusted net present value: What is the current valuation of Pharma Mar’s Ecubectedin?

Pharmaceutical Technology

JUNE 6, 2023

Ecubectedin is a small molecule commercialized by Pharma Mar, with a leading Phase II program in Hormone Sensitive Breast Cancer. According to Globaldata, it is involved in 5 clinical trials, which are ongoing. Its development pipeline includes PM14 for solid tumors, among others. It is administered through intravenous route.

Hormones 100
Hormones In-Vitro Genotype Bacteria 100
article thumbnail

Global Roundup: Overland Pharma Launches in China to Provide Access to Breakthrough Therapies

The Pharma Data

DECEMBER 9, 2020

The aim of the research will be to create a TGS IVD platform by optimizing a multi-layer approach encompassing the initial sample and library preparation, state-of-the-art sequencing technologies and improved genotyping procedures. Amolyt has also acquired an option to license the identified candidates for future clinical development.

In-Vivo 52
In-Vivo In-Vitro Antibody Development 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 32,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024